Liquid Biopsy for CNS Lymphoma: CSF Exosomes and CSF Exosomal MiR-15a, MiR-21, MiR-155, MiR-210, and MiR-19b Are Promising Biomarkers for Diagnosis

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2024 Oct 3

PMID 39361107

Authors

Mustafa Aziz Hatiboglu

Busra Karacam

Imran Khan

Kerime Akdur

Elif Burce Elbasan

Sadaf Mahfooz

Mehmet Hakan Seyithanoglu

Guven Cetin

Meliha Gundag Papaker

Mustafa Namik Oztanir

Affiliations

Soon will be listed here.

Abstract

Background: Central nervous system lymphoma (CNSL) is a devastating disease with a poor prognosis. Early diagnosis, monitoring of the treatment response, and outcome prediction carry the utmost importance in the management of patients with CNSL. Surgical biopsy is the gold standard for tissue diagnosis, however, this procedure has potential complications. Therefore, there is a need for a method that provides information about diagnosis and patient monitoring to avoid surgical risks. The study aimed to investigate potential diagnostic biomarkers for patients with CNSL.

Methods And Results: Patients with secondary CNSL were included in this study. Serum and cerebrospinal fluid (CSF) samples were collected before treatment and after completion of the treatment. Cell-free DNA (cfDNA), exosomes, free and exosomal microRNA (miR)-15a, miR-21, miR-155, miR-210, and miR-19b in both serum and CSF were examined, and they were compared with the controls. Also, their levels before and after treatment were compared. Nine patients with the diagnosis of secondary CNSL were reviewed. cfDNA, miR-15a, and miR-155 in serum, and exosome in CSF were found to be significantly higher in CNSL patients compared to the controls. Exosomal miR-15a, miR-21, miR-155, miR-210, and miR-19b in CSF were found to be significantly higher in CNSL patients compared to controls, whereas their levels in serum were not significantly high.

Conclusions: Our findings suggested that exosomes and exosomal miR-15a, miR-21, miR-155, miR-210 and miR-19b in CSF would be promising biomarkers for the diagnosis of patients with CNSL. Further studies are needed to confirm our findings.

References

Bellinzona M, Roser F, Ostertag H, Gaab R, Saini M . Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: a series of 33 cases. Eur J Surg Oncol. 2005; 31(1):100-5. DOI: 10.1016/j.ejso.2004.10.002. View

Hanif F, Muzaffar K, Perveen K, Malhi S, Simjee S . Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017; 18(1):3-9. PMC: 5563115. DOI: 10.22034/APJCP.2017.18.1.3. View

Correia C, Schaff L, Grommes C . Central Nervous System Lymphoma: Approach to Diagnosis and Treatment. Cancer J. 2020; 26(3):241-252. DOI: 10.1097/PPO.0000000000000449. View

Kuker W, Nagele T, Korfel A, Heckl S, Thiel E, Bamberg M . Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005; 72(2):169-77. DOI: 10.1007/s11060-004-3390-7. View

Zacharia T, Law M, Naidich T, Leeds N . Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging. 2008; 18(4):411-7. DOI: 10.1111/j.1552-6569.2007.00231.x. View

Behin A, Hoang-Xuan K, Carpentier A, Delattre J . Primary brain tumours in adults. Lancet. 2003; 361(9354):323-31. DOI: 10.1016/S0140-6736(03)12328-8. View

Grommes C, DeAngelis L . Primary CNS Lymphoma. J Clin Oncol. 2017; 35(21):2410-2418. PMC: 5516483. DOI: 10.1200/JCO.2017.72.7602. View

Josephson S, Papanastassiou A, Berger M, Barbaro N, McDermott M, Hilton J . The diagnostic utility of brain biopsy procedures in patients with rapidly deteriorating neurological conditions or dementia. J Neurosurg. 2007; 106(1):72-5. DOI: 10.3171/jns.2007.106.1.72. View

Roth P, Wick W, Weller M . Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010; 23(6):597-602. DOI: 10.1097/WCO.0b013e32833e5a5d. View

10.

Nikanjam M, Kato S, Kurzrock R . Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022; 15(1):131. PMC: 9465933. DOI: 10.1186/s13045-022-01351-y. View

11.

Iriyama C, Murate K, Iba S, Okamoto A, Goto N, Yamamoto H . Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases. Cancer Med. 2023; 12(16):16972-16984. PMC: 10501233. DOI: 10.1002/cam4.6329. View

12.

Benesova L, Belsanova B, Suchanek S, Kopeckova M, Minarikova P, Lipska L . Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem. 2012; 433(2):227-34. DOI: 10.1016/j.ab.2012.06.018. View

13.

Marzese D, Hirose H, Hoon D . Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. Expert Rev Mol Diagn. 2013; 13(8):827-44. DOI: 10.1586/14737159.2013.845088. View

14.

Hench J, Hultschig C, Bratic Hench I, Sadasivan H, Yaldizli O, Hutter G . Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid. Acta Neuropathol. 2024; 148(1):36. PMC: 11371845. DOI: 10.1007/s00401-024-02793-z. View

15.

Heitzer E, Ulz P, Geigl J . Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2014; 61(1):112-23. DOI: 10.1373/clinchem.2014.222679. View

16.

Andersen R . Tumor-specific methylations in circulating cell-free DNA as clinically applicable markers with potential to substitute mutational analyses. Expert Rev Mol Diagn. 2018; 18(12):1011-1019. DOI: 10.1080/14737159.2018.1545576. View

17.

Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F . Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008; 319(5867):1244-7. DOI: 10.1126/science.1153124. View

18.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

19.

Sole C, Arnaiz E, Lawrie C . MicroRNAs as Biomarkers of B-cell Lymphoma. Biomark Insights. 2018; 13:1177271918806840. PMC: 6195009. DOI: 10.1177/1177271918806840. View

20.

Vannini I, Fanini F, Fabbri M . Emerging roles of microRNAs in cancer. Curr Opin Genet Dev. 2018; 48:128-133. PMC: 5986298. DOI: 10.1016/j.gde.2018.01.001. View